CCL19 as a chemokine risk factor for posttreatment lyme disease syndrome: A prospective clinical cohort study

John N. Aucott, Mark J. Soloski, Alison W. Rebman, Lauren A. Crowder, Lauren J. Lahey, Catriona A. Wagner, William H. Robinson, Kathleen T. Bechtold

Research output: Contribution to journalArticlepeer-review

25 Scopus citations


Approximately 10% to 20% of patients optimally treated for early Lyme disease develop persistent symptoms of unknown pathophysiology termed posttreatment Lyme disease syndrome (PTLDS). The objective of this study was to investigate associations between PTLDS and immune mediator levels during acute illness and at several time points following treatment. Seventy-six participants with physician-documented erythema migrans and 26 healthy controls with no history of Lyme disease were enrolled. Sixty-four cytokines, chemokines, and inflammatory markers were measured at each visit for a total of 6 visits over 1 year. An operationalized definition of PTLDS incorporating symptoms and functional impact was applied at 6 months and 1 year following treatment completion, and clinical outcome groups were defined as the return-to-health, symptoms-only, and PTLDS groups. Significance analysis of microarrays identified 7 of the 64 immune mediators to be differentially regulated by group. Generalized logit regressions controlling for potential confounders identified posttreatment levels of the T-cell chemokine CCL19 to be independently associated with clinical outcome group. Receiver operating characteristic analysis identified a CCL19 cutoff of >111.67 pg/ml at 1 month following treatment completion to be 82% sensitive and 83% specific for later PTLDS. Wespeculate that persistently elevated CCL19 levels among participants with PTLDS may reflect ongoing, immune-driven reactions at sites distal to secondary lymphoid tissue. Our findings suggest the relevance of CCL19 both during acute infection and as an immunologic risk factor for PTLDS during the posttreatment phase. Identification of a potential biomarker predictor for PTLDS provides the opportunity to better understand its pathophysiology and to develop early interventions in the context of appropriate and specific clinical information.

Original languageEnglish (US)
Pages (from-to)757-766
Number of pages10
JournalClinical and Vaccine Immunology
Issue number9
StatePublished - Sep 2016

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Clinical Biochemistry
  • Microbiology (medical)


Dive into the research topics of 'CCL19 as a chemokine risk factor for posttreatment lyme disease syndrome: A prospective clinical cohort study'. Together they form a unique fingerprint.

Cite this